Biologic Outcomes in Severe Asthma by Smoking Status: Insights from the SHARP European Registry

Highlights

• The SHARP registry demonstrates comparable efficacy of biologic therapies in severe asthma patients across never-smokers, ex-smokers, and current smokers.
• Improvements in symptom control, asthma-related quality of life, exacerbation frequency, and oral corticosteroid use were consistent regardless of smoking pack-year history.
• Despite evidence, a notable proportion of European clinicians remain reluctant to prescribe biologics to current smokers, reflecting gaps between guidelines and practice.
• The findings emphasize the necessity of targeted randomized controlled trials involving smokers to refine asthma treatment guidelines inclusively.

Background